13F net value change of -$1.21B, net sellers outpacing buyers 403 to 348, and exits (124) exceeding new buys (80)—clear institutional distribution. No insider activity reported to offset the outflow.

Confirmation

Continued net selling in next quarter’s 13F would strengthen the bearish case.

Invalidation Risk

A sudden surge of large new institutional buyers or insider buying would invalidate this verdict.

The above is AI-generated from public regulatory filings and summarizes historical data only. It is not investment advice and should not be used as the basis for any buy or sell decision.

Insider Trading (Form 4)

Form 144 Pre-Sale Notices

No Form 144 planned sale filings in the last 90 days

Beneficial Ownership (13D/13G)

No Schedule 13D/13G filings for this ticker

Material Events (8-K)

Filings (14d)

Data as of 2026-07-14

2026-07-14

West Pharmaceutical Services (WST) and Daikyo Seiko have entered into new long-term agreements that replace their previous technology exchange, cross-license, and distribution deals. The companies will share technical know-how and collaborate on developing components for pharmaceutical packaging such as vials, syringes, and cartridges. West becomes the exclusive distributor for Daikyo products outside Japan, while Daikyo is a non-exclusive distributor for West products in Japan. The agreements run for 10 years.

View Full Filing (SEC EDGAR)

View all Form 8-K filings

FAQ

Who are the top institutional investors holding WEST PHARMACEUTICAL SERVICES (WST)?

Major stakeholders currently include BlackRock, Inc. ($1.7B), Vanguard Capital Management LLC ($1.2B), Vanguard Portfolio Management LLC ($1.0B). Based on the latest 13F filings, there are a total of 753 tracked investment funds and institutions maintaining positions in WST.

What is the overall institutional sentiment toward WST recently?

Institutional sentiment appears Bearish (Net Selling). During the most recent reporting quarter, the stock experienced a net outflow of $1.2B, driven by 348 managers accumulating shares while 403 reduced their exposure.

Which institutions have been selling or reducing their WST positions?

In the latest period, 279 funds trimmed their holdings, and 124 managers completely exited their positions. The aggregate reported sell value was $7.5B.

Are there any notable investors adding WST to their portfolios?

Yes, buying activity remains notable. 80 institutions opened new positions in {ticker}, and 268 existing holders added to their shares. The total reported buy value for the quarter amounted to $10.3B.